Cedars-Sinai appoints division director for hematology, cell therapy
Click Here to Manage Email Alerts
John P. Chute, MD, has been appointed director of the division of hematology and cellular therapy in the department of medicine at Cedars-Sinai Cancer.
Chute also will serve as director of the Center for Myelodysplastic Diseases Research, as well as associate director of the Board of Governors Regenerative Medicine Institute in the department of biomedical sciences.
His appointments took effect Nov. 23.
Chute previously served as professor of medicine and radiation oncology at David Geffen School of Medicine at UCLA, as well as investigator in the Broad Stem Cell Research Center.
He is recognized for his research into hematopoietic stem cells. His lab has discovered several growth factors that play important roles in blood-forming stem cell regeneration.
“Dr. Chute is an exceptional addition to our faculty,” Dan Theodorescu, MD, PhD, director of Cedars-Sinai Cancer, said in a press release. “His international reputation as a physician-scientist who has made major contributions to stem cell and hematopoietic cell biology will greatly contribute to positioning the newly created division of hematology and cell therapy as one of the best in the nation, while providing Cedars-Sinai Cancer patients with exciting new options for the treatment of blood malignancies.”
In his new role, Chute intends to expand chimeric antigen receptor (CAR) T-cell therapy research.
“I’m excited to join the Cedars-Sinai Cancer faculty because of the opportunity to collaborate with the world-class scientists and top-tier physicians at the cancer center,” Chute said. “Cedars-Sinai has always been a leading medical center and is deeply committed to basic and translational research, while also growing the hematology and cellular therapy specialties. I’m eager to play a leading role in that growth.”
Read more about
Click Here to Manage Email Alerts